Latest news with #NovoviahPharmaceuticals
The Independent
12-06-2025
- Health
- The Independent
New test for coeliac disease could increase diagnosis rates
A new blood test for gluten -specific T cells can detect coeliac disease even without gluten consumption, according to research published in Gastroenterology. The new blood test could increase diagnosis rates, identify those at risk of severe reactions, and detect silent coeliac disease. The test measures the immune marker interleukin 2 (IL-2), which spikes in the bloodstream of people with coeliac disease after gluten consumption. The study showed the test could detect coeliac disease with up to 90 per cent sensitivity and 97 per cent specificity, even in patients on a gluten -free diet. Researchers are collaborating with Novoviah Pharmaceuticals to confirm the test's accuracy across diverse populations and gather real-world data, potentially leading to faster and safer diagnoses. 'Game-changer' new blood test to detect prevalent autoimmune disease without nightmare side effects
Yahoo
10-06-2025
- Health
- Yahoo
Novel T Cell Measurement System by Novoviah Pharmaceuticals Demonstrates High Accuracy for Clinical Disease Detection and Monitoring of Celiac Disease
BRISBANE, Australia, June 10, 2025--(BUSINESS WIRE)--Novoviah Pharmaceuticals announces that their novel clinical platform technology for detecting and monitoring disease by measuring immune reactivity has been successfully tested in Celiac Disease, with results published in Gastroenterology. The NovoleukinTM test platform, developed specifically for clinical use, measures T Cell reactivity in fresh whole blood after 24-hour in vitro stimulation with a target antigen. The proprietary technology boosts T Cell activity after blood collection, enabling accurate cytokine biomarker measurement and comparison with unstimulated controls. This can be used to monitor disease reactivity status and the effectiveness of prospective therapeutics. Originally developed for multi-center clinical trials, the NovoleukinTM system has potential for broader clinical use. Its utility and performance were demonstrated in collaboration with WEHI researchers who analyzed blood samples from 181 volunteers to identify the presence and assess the severity of celiac disease. The results show high sensitivity (90%) and specificity (95%) in detecting celiac disease, even in patients following a strict gluten free diet which normally confounds traditional diagnostic methods. The test detects as few as one gluten-specific T lymphocyte in one milliliter of blood or one per million CD4+ T cells. This level of sensitivity in a straightforward blood test is a landmark technical achievement and promises to impact patient care in many fields and accelerate immunotherapy and vaccine development. Associate Professor Jason Tye-Din, Head of WEHI's Celiac Research Laboratory and a gastroenterologist at the Royal Melbourne Hospital, highlighted the test's promise for simplifying diagnosis and removing a significant barrier in current diagnostics. "By stimulating T cells after a blood draw, patients can avoid the need to return to gluten and the suffering that often comes with that – for the sole purpose of diagnosis. That is a major step towards improving outcomes for patients." The test was also predictive of patient responses during gluten challenge protocols, underscoring its utility in stratifying patients for clinical research and tailoring therapeutic strategies. Dr Robert Anderson, co-founder of Novoviah Pharmaceuticals, current President of the International Society for the Study of Celiac Disease and a practicing gastroenterologist, said the study highlights the potential of practical, blood-based T cell diagnostics in clinic and for clinical trials. "The test is designed for ease of use in the clinical setting. It can be prepared without specialist equipment and then sent for highly sensitive laboratory analysis. The protocol is simple and reproducible enabling easy rollout across multiple sites," Dr Anderson said. The Novoleukin test's ability to detect disease and measure changes in immune response has proven invaluable in the developmental journey for drug developers. "Non-invasively monitoring T cell reactivity opens the door to transformative clinical applications, particularly in drug development," Dr Anderson added. "The platform is already being used by leading biopharma partners to evaluate immune responses during celiac disease clinical trials, offering real-time insights into treatment efficacy." Novoviah is actively expanding the diagnostic applications of the Novoleukin platform across additional immune-mediated diseases, including viral infection, autoimmune conditions and some cancers, aiming to bring T cell-guided insights to clinical and research settings. About Novoviah Pharmaceuticals Novoviah is a Brisbane-based biotechnology company established in 2020 to develop and supply a new best in-class NovoleukinTM antigen-specific T cell testing platform for clinical trials and explore its broader application in clinical care. Novoviah is committed to advancing sensitive and reliable clinical tests for antigen-specific T cells to support drug developers, researchers, clinicians and patients needing better treatments and diagnosis. Find out more at About WEHI (Walter and Eliza Hall Institute of Medical Research) WEHI is where brilliant minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancer, infection and immunity, and lifelong health. WEHI brings together diverse and creative people with different experience and expertise to solve some of the world's most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together. Find out more at View source version on Contacts Novoviah Pharmaceuticalskylieell@ +61413496222 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
10-06-2025
- Health
- Business Wire
Novel T Cell Measurement System by Novoviah Pharmaceuticals Demonstrates High Accuracy for Clinical Disease Detection and Monitoring of Celiac Disease
BRISBANE, Australia--(BUSINESS WIRE)--Novoviah Pharmaceuticals announces that their novel clinical platform technology for detecting and monitoring disease by measuring immune reactivity has been successfully tested in Celiac Disease, with results published in Gastroenterology. "Non-invasively monitoring T cell reactivity opens the door to transformative clinical applications, particularly in drug development." The Novoleukin TM test platform, developed specifically for clinical use, measures T Cell reactivity in fresh whole blood after 24-hour in vitro stimulation with a target antigen. The proprietary technology boosts T Cell activity after blood collection, enabling accurate cytokine biomarker measurement and comparison with unstimulated controls. This can be used to monitor disease reactivity status and the effectiveness of prospective therapeutics. Originally developed for multi-center clinical trials, the Novoleukin TM system has potential for broader clinical use. Its utility and performance were demonstrated in collaboration with WEHI researchers who analyzed blood samples from 181 volunteers to identify the presence and assess the severity of celiac disease. The results show high sensitivity (90%) and specificity (95%) in detecting celiac disease, even in patients following a strict gluten free diet which normally confounds traditional diagnostic methods. The test detects as few as one gluten-specific T lymphocyte in one milliliter of blood or one per million CD4+ T cells. This level of sensitivity in a straightforward blood test is a landmark technical achievement and promises to impact patient care in many fields and accelerate immunotherapy and vaccine development. Associate Professor Jason Tye-Din, Head of WEHI's Celiac Research Laboratory and a gastroenterologist at the Royal Melbourne Hospital, highlighted the test's promise for simplifying diagnosis and removing a significant barrier in current diagnostics. 'By stimulating T cells after a blood draw, patients can avoid the need to return to gluten and the suffering that often comes with that – for the sole purpose of diagnosis. That is a major step towards improving outcomes for patients.' The test was also predictive of patient responses during gluten challenge protocols, underscoring its utility in stratifying patients for clinical research and tailoring therapeutic strategies. Dr Robert Anderson, co-founder of Novoviah Pharmaceuticals, current President of the International Society for the Study of Celiac Disease and a practicing gastroenterologist, said the study highlights the potential of practical, blood-based T cell diagnostics in clinic and for clinical trials. 'The test is designed for ease of use in the clinical setting. It can be prepared without specialist equipment and then sent for highly sensitive laboratory analysis. The protocol is simple and reproducible enabling easy rollout across multiple sites,' Dr Anderson said. The Novoleukin test's ability to detect disease and measure changes in immune response has proven invaluable in the developmental journey for drug developers. 'Non-invasively monitoring T cell reactivity opens the door to transformative clinical applications, particularly in drug development,' Dr Anderson added. 'The platform is already being used by leading biopharma partners to evaluate immune responses during celiac disease clinical trials, offering real-time insights into treatment efficacy.' Novoviah is actively expanding the diagnostic applications of the Novoleukin platform across additional immune-mediated diseases, including viral infection, autoimmune conditions and some cancers, aiming to bring T cell-guided insights to clinical and research settings. About Novoviah Pharmaceuticals Novoviah is a Brisbane-based biotechnology company established in 2020 to develop and supply a new best in-class Novoleukin TM antigen-specific T cell testing platform for clinical trials and explore its broader application in clinical care. Novoviah is committed to advancing sensitive and reliable clinical tests for antigen-specific T cells to support drug developers, researchers, clinicians and patients needing better treatments and diagnosis. Find out more at About WEHI (Walter and Eliza Hall Institute of Medical Research) WEHI is where brilliant minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancer, infection and immunity, and lifelong health. WEHI brings together diverse and creative people with different experience and expertise to solve some of the world's most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together.
ABC News
09-06-2025
- Health
- ABC News
New coeliac disease blood test set to enable diagnosis on gluten-free diets
Eating gluten was making Eliza Long sick, but it was the only way for her to get a life-altering diagnosis. Aged 11, she underwent a gastroscopy at the Royal Children's Hospital in Melbourne, with a biopsy revealing she had coeliac disease. More than 350,000 Australians live with the disease, caused by an immune reaction to the gluten protein found in wheat, rye and barley. Current testing requires patients to eat gluten for weeks beforehand, in what is called the gluten challenge. "Knowing that what I was eating was going to make me feel really unwell was quite concerning," Ms Long, now aged 23, said. And the lengthy process was "confronting for a kid", she said. Researchers say the gluten challenge puts people off getting answers, with up to 80 per cent of coeliac cases remaining undiagnosed globally. Now, there is hope a "world-first" blood test being developed in Australia can bring that barrier down. Jason Tye-Din is the head of the coeliac research laboratory at the Walter and Eliza Hall Institute of Medical Research (WEHI) and a gastroenterologist at Royal Melbourne Hospital. He said a new test being developed by WEHI researchers with Brisbane-based Novoviah Pharmaceuticals could "revolutionise" the diagnostic process for patients. "It's just a simple blood test, they don't need an invasive gastroscopy and, importantly, they don't even need to be eating gluten for it to be accurate," he said. The test involves mixing a person's blood sample with gluten in a test tube, which then signals whether the T cells that cause coeliac disease are present. Dr Tye-Din said it could improve detection of the disease, particularly among those on gluten-free diets who did not want to eat gluten and make themselves unwell. "It's really important to make a diagnosis of coeliac disease because it can lead to long-term health issues such as gut symptoms, osteoporosis, infertility, even some forms of cancer, such as lymphoma." A study of 181 blood samples from people with and without coeliac disease found a "very high accuracy" for the new test to make a diagnosis or exclude it, even in those on gluten-free diets. In one case, Dr Tye-Din said a patient who had been diagnosed 10 years earlier tested negative, allowing a different diagnosis to be made. "This test allowed us to find the right treatment for her," he said. Researchers are working to confirm the test's accuracy across diverse populations and plan to make it available within the next two years. Ms Long said not having to eat gluten for her diagnosis would have been "life-changing".
